Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro

Wei Li, Andrea Sanchez-Hidalgo, Victoria Jones, Vinicius Calado Nogueira De Moura, E. Jeffrey North, Mary Jackson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

Original languageEnglish (US)
Article numbere02399
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

bedaquiline
Clofazimine
Mycolic Acids
Lactams
Rifampin
Mycobacterium tuberculosis
Urea
Pharmaceutical Preparations
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. / Li, Wei; Sanchez-Hidalgo, Andrea; Jones, Victoria; De Moura, Vinicius Calado Nogueira; North, E. Jeffrey; Jackson, Mary.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 4, e02399, 01.04.2017.

Research output: Contribution to journalArticle

Li, Wei ; Sanchez-Hidalgo, Andrea ; Jones, Victoria ; De Moura, Vinicius Calado Nogueira ; North, E. Jeffrey ; Jackson, Mary. / Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. In: Antimicrobial Agents and Chemotherapy. 2017 ; Vol. 61, No. 4.
@article{23112d3285ce425a9deede864b8abfa0,
title = "Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro",
abstract = "A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.",
author = "Wei Li and Andrea Sanchez-Hidalgo and Victoria Jones and {De Moura}, {Vinicius Calado Nogueira} and North, {E. Jeffrey} and Mary Jackson",
year = "2017",
month = "4",
day = "1",
doi = "10.1128/AAC.02399-16",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro

AU - Li, Wei

AU - Sanchez-Hidalgo, Andrea

AU - Jones, Victoria

AU - De Moura, Vinicius Calado Nogueira

AU - North, E. Jeffrey

AU - Jackson, Mary

PY - 2017/4/1

Y1 - 2017/4/1

N2 - A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

AB - A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

UR - http://www.scopus.com/inward/record.url?scp=85017024884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017024884&partnerID=8YFLogxK

U2 - 10.1128/AAC.02399-16

DO - 10.1128/AAC.02399-16

M3 - Article

C2 - 28115355

AN - SCOPUS:85017024884

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

M1 - e02399

ER -